Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05003362
Other study ID # 2018P001239
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 25, 2020
Est. completion date November 23, 2021

Study information

Verified date July 2023
Source Brigham and Women's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mindfulness Training specifically for pain to be offered to migraine patients


Description:

Patients with high frequency migraine will be randomized to UC or intervention. Those in intervention will attend a multi session training on Acceptance and Commitment Therapy. All participants will track responses.


Recruitment information / eligibility

Status Completed
Enrollment 75
Est. completion date November 23, 2021
Est. primary completion date November 23, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Women ages 18-65 - Diagnosis of episodic migraine (according to International Classification for Headache Diagnosis criteria) - 4-14 migraine days per month over the past 3 months - No change in medication in the past 3 months - Greater than 1 year of migraines - Agreeable to participate, commit to all study procedures and to be randomized to either group - Fluent in English Exclusion Criteria: - Any unstable medical or psychiatric conditions requiring immediate treatment or could lead to difficulty complying with the protocol - Active suicidal ideation - Moderate to severe depression - Current alcohol or substance abuse - Recent Cognitive Behavioral Therapy, Mindfulness Based Cognitive Therapy, Dialectic Behavioral Therapy or Acceptance and Commitment Therapy within past 3 years - Current use of narcotics - Psychiatric hospitalization within past year - Comorbid pain condition rated as more painful than migraine - Starts new migraine treatment during study - Inability to complete study visits

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
ACT
mindfulness intervention for patients with pain/migraine

Locations

Country Name City State
United States Brigham and Womens Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Brigham and Women's Hospital Massachusetts Institute of Technology

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of a randomized controlled trial of ACT Demonstrate that 48 patients can be successfully enrolled and randomized one year
Secondary Preliminary data on the effectiveness of ACT on migraine frequency and migraine disability Patient-completed migraine logs will be used to record the number of migraine days/month. Migraine disability will be measured using the validated Migraine Disability Assessment (MIDAS) questionnaire. one year
Secondary Change in migraine severity, duration, and medication use. Severity of each migraine (1-10), duration (hours), and medicines taken assessed by patient-completed migraine logs. one year
Secondary Change in headache-related disability Headache Related Disability measured using the validated HIT-6. one year
Secondary Change in quality of life. Quality of life assessed using the Migraine Specific Quality of Life Questionnaire (MSQ). one year
Secondary Change in depression and anxiety. Depression and anxiety assessed through the Hospital Anxiety and Depression Scale (HADS). one year
Secondary Change in pain acceptance and pain expectancy. Pain acceptance assessed through the Chronic Pain Acceptance Questionnaire and pain expectancy during the migraine attacks assessed using the allodynia questionnaire. one year
Secondary Change in pain catastrophizing. Pain Catastrophizing Scale (PCS) used to assess distress and rumination experienced due to migraine anticipation. one year
Secondary Change in distress tolerance. Distress tolerance will be assessed through the Distress Tolerance Scale. one year
Secondary Change in physical activity. Physical activity measured using the Godin Leisure Time Exercise questionnaire. one year
Secondary Change in perceived stress. Perceived stress measured through the Perceived Stress Scale (PSS). one year
Secondary Change in mindfulness. Mindful Attention and Awareness Scale (MAAS) used to measure receptive awareness and attention to the present. one year
Secondary Change in cortisol levels. Salivary Cortisol will be collected to measure the cortisol awakening response. one year
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A